Extracted polypeptide binding zalpha11 ligand receptor (versions), polynucleotid encoding it (versions), expression vector (versions) and host cell (versions)

FIELD: chemistry.

SUBSTANCE: invention concerns biotechnology, particularly obtaining cytokine proteins, and can be applied in cell technology. Polypeptide binding Zalpha11 ligand receptor is obtained. Nucleotide sequence coding new polypeptide is introduced into host cell as part of expression vector, and polypeptide is produced.

EFFECT: possibility of efficient adjustment of proliferation and/or development of hemopoietic cells in vitro and in vivo.

14 cl, 1 dwg, 55 ex

 

The text descriptions are given in facsimile form.

1. The selected binding polypeptide receptor Zalphal1-ligand with SEQ I NO: 115, essentially corresponding to the amino acid sequence that is at least 90% identical to residues 41 (Gln) to 148 (Ile)as shown in SEQ ID NO:2.

2. The selected binding polypeptide receptor Zalphal1-ligand with SEQ ID NO: 115, essentially corresponding to the amino acid sequence that is at least 95% identical to residues 41 (Gln) to 148 (Ile)as shown in SEQ ID NO:2.

3. The selected binding polypeptide receptor Zalphal1-ligand with SEQ ID NO: 115, essentially corresponding to the amino acid sequence that is 100% identical to residues 41 (Gln) to 148 (Ile)as shown in SEQ ID NO:2.

4. The selected binding polypeptide receptor Zalphal1-ligand with SEQ ID NO: 115, essentially corresponding to the amino acid sequence that is at least 90% identical to residues 32 (Gln) to 148 (Ile)as shown in SEQ ID NO:2.

5. The selected binding polypeptide receptor Zalphal1-ligand with SEQ ID NO: 115, essentially corresponding to the amino acid sequence that is at least 95% identical to residues 32 (Gln) to 148 (Ile)as shown in SEQ ID NO:2.

6. Selected polynucleotide encoding Zalpha11 ligand-receptor, essentially corresponding nucleotide sequence that determines the amino acid sequence of the polypeptide according to claims 1 to 4 or 5.

7. The expression vector containing the following functional is about related items:

a. promoter transcription;

b. the DNA segment in accordance with claim 6 and,

c. the terminator of transcription.

8. A host cell for production of the polypeptide according to any one of claims 1 to 5, containing the expression vector according to claim 7.

9. The selected polypeptide that binds a Zalpha11 receptor-ligand with SEQ ID NO: 115, essentially corresponding to the amino acid sequence that is at least 90% identical to residues 30 (Gln) to 162 (Ser)as shown in SEQ ID NO:2.

10. The selected polypeptide that binds a Zalpha11 receptor-ligand with SEQ ID NO: 115, essentially corresponding to the amino acid sequence that is at least 95% identical to residues 30 (Gln) to 162 (Ser)as shown in SEQ ID NO:2.

11. The selected polypeptide that binds a Zalpha11 receptor-ligand with SEQ ID NO: 115, essentially corresponding to the amino acid sequence of from 30 (Gln) to 162 (Ser)as shown in SEQ ID NO:2.

12. Selected polynucleotide encoding Zalpha11 ligand-receptor, essentially corresponding nucleotide sequence that determines the amino acid sequence of the polypeptide on PP, 10 or 11.

13. The expression vector containing the following functionally related elements:

a. promoter transcription;

b. the DNA segment in accordance with clause 12 and,

c. the terminator of transcription.

14. A host cell for producing polypep is Yes to any of PP-11, containing the expression vector according to item 13.



 

Same patents:

FIELD: chemistry; biochemistry.

SUBSTANCE: present invention pertains to medicine, and particularly to immunotherapy. Proposal is given of a method of obtaining and/or multiplication of monocytic origin self-specific regulatory T-cells, co-expressing CD3 and CD14 antigens on their surface. The cells are suitable for preventing and/or curing diseases, caused by violation of self-tolerance, particularly, auto-immune diseases and allergies, as well as for production of pharmaceutical preparations. The given cells are self-specific for a patient, on which they are used.

EFFECT: design of a method of obtaining and/or multiplication of monocytic origin self-specific regulatory T-cells.

38 cl, 9 ex, 4 tbl, 12 dwg

FIELD: chemistry; biochemistry.

SUBSTANCE: present invention pertains to molecular biology and bioengineering, and particularly to stem cells. Proposal is given of a composition for inhibiting proliferation of stem cells of a mammal, enclosed in a structure, containing agarose, as well as methods of inhibiting other cells, not entrapped, including stem cells and cancerous and/or hyper-proliferative cells.

EFFECT: obtaining a composition for treating cell proliferative diseases.

26 cl, 5 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: present invention pertains to molecular biology and bioengineering, and particularly to stem cells. Proposal is given of a composition for inhibiting proliferation of stem cells of a mammal, enclosed in a structure, containing agarose, as well as methods of inhibiting other cells, not entrapped, including stem cells and cancerous and/or hyper-proliferative cells.

EFFECT: obtaining a composition for treating cell proliferative diseases.

26 cl, 5 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: present invention pertains to versions of compositions used for separating cells, particularly blood cells, containing dextran, an antibody against glycophorin A, anti-CD 15 antibody, anti-CD 9 antibody, anti-CD 94 antibody, anti-CD 161 antibody and if necessary, other anti-CD antibodies and other components, necessary for dividing cells, particularly heparin and bivalent cations. An assembly and a method of separating cells using the assembly are invented. The invented compositions and method allow for agglutination of cells through identification of their surface, and can be used for identifying even rare cells with high output.

EFFECT: agglutination of cells through identification of their surface.

50 cl, 4 dwg, 19 tbl, 14 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: present invention pertains to versions of compositions used for separating cells, particularly blood cells, containing dextran, an antibody against glycophorin A, anti-CD 15 antibody, anti-CD 9 antibody, anti-CD 94 antibody, anti-CD 161 antibody and if necessary, other anti-CD antibodies and other components, necessary for dividing cells, particularly heparin and bivalent cations. An assembly and a method of separating cells using the assembly are invented. The invented compositions and method allow for agglutination of cells through identification of their surface, and can be used for identifying even rare cells with high output.

EFFECT: agglutination of cells through identification of their surface.

50 cl, 4 dwg, 19 tbl, 14 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: present invention pertains to versions of compositions used for separating cells, particularly blood cells, containing dextran, an antibody against glycophorin A, anti-CD 15 antibody, anti-CD 9 antibody, anti-CD 94 antibody, anti-CD 161 antibody and if necessary, other anti-CD antibodies and other components, necessary for dividing cells, particularly heparin and bivalent cations. An assembly and a method of separating cells using the assembly are invented. The invented compositions and method allow for agglutination of cells through identification of their surface, and can be used for identifying even rare cells with high output.

EFFECT: agglutination of cells through identification of their surface.

50 cl, 4 dwg, 19 tbl, 14 ex

FIELD: medicine; cellular technologies.

SUBSTANCE: method of production of skin cell culture includes skin explants sampling and placing of fragments thereof into Petri dish, filling with culture medium, followed by cultivation and removal of produced culture. Herewith explant pieces are fixed, pressing it to Petri dish surface with glass plate inserted in brace of Petri dish. Pressing plate area is 40-70% of Petri dish area, and number of fixation points (plate angles) is at least three, with plate thickness at least 0.5 mm. Grown cell culture is collected not only from Petri dish surface, and also from pressing plate surface. Invention allows for produced skin cell culture in great volume for short time period.

EFFECT: reliable fixation of explants fragments, higher efficiency and acceleration of skin call cultivation.

1 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: substance of invention includes separated population of hematopoetic stem cells of negative lineage, (Lin- HSC), containing progenitor endotheliocytes (EPC), protecting retina blood vessels and neuronal eye networks, method of separation of hematopoetic stem cell population of negative lineage from bone marrow of mammal adult, herewith approximately 20% of cells in separated Lin- HSC express cell surface CD31.

EFFECT: possibility to apply for treatment of eye vascular diseases.

22 cl, 10 ex, 24 dwg

FIELD: medicine.

SUBSTANCE: substance of invention includes separated population of hematopoetic stem cells of negative lineage, (Lin- HSC), containing progenitor endotheliocytes (EPC), protecting retina blood vessels and neuronal eye networks, method of separation of hematopoetic stem cell population of negative lineage from bone marrow of mammal adult, herewith approximately 20% of cells in separated Lin- HSC express cell surface CD31.

EFFECT: possibility to apply for treatment of eye vascular diseases.

22 cl, 10 ex, 24 dwg

FIELD: medicine.

SUBSTANCE: substance of invention includes separated population of hematopoetic stem cells of negative lineage, (Lin- HSC), containing progenitor endotheliocytes (EPC), protecting retina blood vessels and neuronal eye networks, method of separation of hematopoetic stem cell population of negative lineage from bone marrow of mammal adult, herewith approximately 20% of cells in separated Lin- HSC express cell surface CD31.

EFFECT: possibility to apply for treatment of eye vascular diseases.

22 cl, 10 ex, 24 dwg

FIELD: chemistry, biotechnology.

SUBSTANCE: invention relates to field of biotechnology and concerns obtaining factor VII protein by method of recombinant DNA. Recombinant plasmid DNA was constructed for expression of blood clotting factor VII in mammalian cells, which is product of ligating of fragment of cDNA of human factor VII gene, flanked by sites of restrictases Xhol and BamHI recognising, with large XhoI/BglII fragment of vector pEFZeo, including genes of resistance to ampicillin and zeocin. As result of BHK cell transformation with new recombinant plasmid, cell line BHK/F7 was obtained, which produces recombinant protein of factor VII with output of up to 40 mkg/ml.

EFFECT: obtaining cell line producing recombinant protein of factor VII.

2 cl, 4 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: invention concerns genetic engineering, biotechnology, immunology and medicine and can be applied in obtaining antitumoral vaccine and melanoma treatment. Vaccine compositions are based on heat shock proteins and antigen peptides for treatment of tumor disease, the said compositions containing hybrid protein consisting of heat shock HSP70 family protein and one of specific melanoma MAGE peptides (A1, A2, A3) or gp 100, as well as suitable pharmaceutical carrier. The invention also claims a method for obtaining the said hybrid proteins by gene expression in synthetic recombinant vectors in producer strains of E coli BL21 (DE3) cells.

EFFECT: improved immunising power.

3 cl, 4 ex, 1 tbl, 2 dwg

FIELD: biotechnology, genetic engineering.

SUBSTANCE: invention describes recombinant plasmid DNAs constructed in vitro that comprise artificial genes for light and heavy chains of full-scale human antibody prepared by genetic engineering methods. These genes are created on basis of variable fragments of light and heavy chains of recombinant antibody 1F4 and constant human genes IgG1, cytomegalovirus promoter and polyadenylation site BGH. Plasmids provide biosynthesis of recombinant full-scale human antibodies of class IgG1 in mammalian cells. These antibodies interact specifically with smallpox vaccine virus. The affinity constant for prepared recombinant antibodies is 3.54 x 109 ± 0.38 x 109 M-1. Plasmids are used by combined transfection of human cells HEK 293T. Prepared full-scale recombinant antibody against protein of size 27 kDa of smallpox virus vaccine can be used as a base for creature of pharmaceutical preparations used for diagnosis of some post-vaccine complications caused by smallpox virus vaccine. Also, preparations will comprise decreased therapeutic doses of immunoglobulins that will provide minimal undesirable immune response in patients after administration of the preparation.

EFFECT: valuable medicinal properties of plasmid DNA.

4 cl, 7 dwg, 6 ex

FIELD: biotechnology, medicine, immunology.

SUBSTANCE: invention relates to recombinant vaccine against HIV-1 that represents a combination of immunogens as micelle-like particles comprising recombinant plasmid DNA pcDNA-TCI covered by conjugate spermidine-polyglucine with recombinant protein TBI comprising conservative T- and B-cellular virus-neutralizing epitopes in the stabilizing system. In immunization using this created vaccine production of specific antibodies possessing the virus-neutralizing activity is induced as well specific cytotoxic immune response also.

EFFECT: valuable medicinal properties of vaccine.

1 tbl, 5 dwg, 5 ex

FIELD: medicine, immunology.

SUBSTANCE: the present innovation deals with specific prophylaxis of smallpox and viral hepatitis B. The kit contains two tablets each contains stabilizing additives, a filler and lyophilized alive viral material worked out based upon recombinant VOV strain at typical VOV properties expressing proteins preS2-S and HBs virus of hepatitis B virus, the first immunizing dosage corresponds to minimal quantity of viral material being sufficient to obtain weak immune response in the body in case of insignificant at insignificant reactogenicity, and immunizing dosage of the second - maximal quantity of viral material that causes pronounced and prolong immune response in the body at no negative side action. The technique of applying the kit of bivaccine tablets, first, one should use the 1st tablet at minimal dosage of bivaccine, as for the 2nd tablet - with maximal dosage of bivaccine it should be taken till the moment of developing humoral answer (in 7-14 d) after injecting the 1st tablet at minimal immunizing dosage of bivaccine. The innovation enables to create stable immunity.

EFFECT: higher efficiency.

4 cl, 5 ex, 6 tbl

FIELD: gene engineering.

SUBSTANCE: invention relates to method for modification target endogenic gene or chromosomal locus in eucaryotic cells. Claimed method includes production of large cloned genomic fragment having more than 20000 n.p. and designing based on the same large targeting vector (LTVEC) by using bacterial homological recombination. Further LTVEC is introduced into eucaryotic cells to modify endogenic gene or chromosomal locus. Finally assay is carried out to determine of allele modification in such cells. Also disclosed is application said cells for generation of organisms carrying such genetic modification.

EFFECT: method for modification with large DNA sequences.

26 cl, 6 dwg, 2 tbl, 5 ex

FIELD: molecular biology, biochemistry, medicine, oncology.

SUBSTANCE: invention relates to DNA sequences found in analysis of mDNA from squamous carcinoma cellular lines of different origin wherein these DNA sequences represent transcripts from rearranged genes SCCA1 and SCCA2. Result of rearrangement is formation of fused gene consisting of exon 2-7 of gene SCCA1 and exon 8 of gene SCCA2, or exons 2-7 of gene SCCA2 and exon 8 of gene SCCA1. Prepared expressing vectors comprising above said combinations of exons of two genes provide synthesis of corresponding fused protein in host-cell. Proposed sequences of nucleic acids and genetic constructions based on thereof represent novel agents for diagnosis squamous carcinomas.

EFFECT: valuable biological and medicinal properties of transcripts.

8 cl, 9 dwg, 1 tbl, 5 ex

FIELD: biotechnology, in particular isolated DNA molecule providing plant disease resistance and method for providing of disease resistance to plants.

SUBSTANCE: DNA molecular containing N1M1 is isolated. Recombinant vector including active in plant promoter functionally bonded with said DNA is constructed and plant is transformed by this vector.

EFFECT: decreased technological charges and increased land productivity.

9 cl, 37 dwg, 18 tbl, 10 ex

FIELD: chemistry, biochemistry.

SUBSTANCE: invention relates to biotechnology and to methods of producing vaccine preparations with the help of gene engineering and immunology. The invention proposes the expressive plasmid DNA p-BMC-gag (A)-hum, containing an artificial gene gag (A)-hum, for expression of p55 protein in eukaryote cell. The invention can be used in medicine and allied industries ensure a 10-12-fold increase in expression of p55 protein of the human immunodeficiency virus of the 1st type in eukaryote cells.

EFFECT: high-efficiency method of producing vaccine preparations gene engineering and immunology.

1 cl, 2 dwg, 2 tbl, 4 ex

Up!